-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $33

Benzinga·04/21/2026 13:19:41
Listen to the news
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $33.